Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer ...
First-in-class antibody-drug conjugate (ADC) that targets Nectin-4, which is a cell surface protein highly expressed in bladder cancer. Preclinical data suggest that the anticancer activity of it is ...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1 study ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A prospective phase II clinical study of different time-delivered drugs combined with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma. This is an ASCO Meeting Abstract ...
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that first preclinical data for its asset IPH45, a ...
Nectin cell adhesion molecule 4 (Nectin-4) overexpression in different tumors correlates with cancer progression and poor prognosis in many human malignancies. The first Nectin-4-targeting antibody, ...
Corbus Pharmaceuticals ( (CRBP)) has shared an update. Corbus Pharmaceuticals presented an updated corporate overview dated February 25, 2026, highlighting a diversified pipeline led by CRB-701, a ...
Nectin-4 has been successfully established as a target molecule in locally advanced and metastatic bladder cancer. An antibody-drug conjugate (enfortumab-vedotin) directed against nectin-4 has shown ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
“ In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.” Nectin-4 has been ...
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results